secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001447362-21-000250
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Q3 revenue $23.5M (+54% YoY); guides FY21 $89-93M; acquiring Cernostics
------------------------------------------------------------------------------

- Q3 revenue $23.5M, up 54% vs $15.2M in Q3 2020; adjusted revenue $23.6M, up 71%.
- Total test reports 7,727 (vs 4,779); DecisionDx-Melanoma 5,505 (+25%), DecisionDx-SCC 934.
- Gross margin 77.9%; adjusted 80.9%; cash $363M as of Sept 30, 2021.
- Signed definitive agreement to acquire Cernostics (TissueCypher BE test) to expand TAM by ~$1B; close expected by year-end 2021.
- On track to meet raised FY21 revenue guidance of $89-93M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736221000250/0001447362-21-000250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736221000250/cstl-20211108.htm
  HTML page:      https://secwatch.observer/filing/0001447362-21-000250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer